Allogene Therapeutics advances ALLO-329 cell therapy to transform autoimmune care

Allogene Therapeutics advances ALLO-329 cell therapy to transform autoimmune care
@AllogeneTx: Allogene advances ALLO-329 therapy

Allogene Therapeutics is making strides with its investigational ALLO-329, an 'off-the-shelf' AlloCAR T™ therapy aimed at treating autoimmune diseases. The product is empowered by Allogene's proprietary Dagger® technology, designed to reset the immune system and expand access to transformative care.

The company underscores its mission to innovate in the field of cellular therapies with ALLO-329, which aims to offer new therapeutic options. This investigational treatment reflects Allogene Therapeutics' continued commitment to fostering breakthroughs in immune system management and enhancing patient care.

Allogene Therapeutics’ latest advances in immune system management further build on its ongoing initiatives to expand therapeutic frontiers. These developments align with the company’s earlier efforts to advance autoimmune disease treatment, as seen in its launch of the RESOLUTION trial targeting lupus. The focus on innovation is also reflected in senior leadership’s advocacy for next-generation strategies, as outlined during the Jefferies Global Healthcare Conference.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.